BioNTech Bets €16.8 Billion on a 2026 Oncology Milestone as Restructuring Costs Mount

The clock is ticking for BioNTech’s ambitious oncology pivot. The Mainz-based biotech is burning through cash at a rapid clip to fund an aggressive clinical program, yet management insists its first cancer drug approval will land before the calendar turns to 2027. To bridge the gap, the company has authorized a $1 billion share buyback and is simultaneously slashing 1,860 jobs — a move that has left investors unsettled.

Shares slipped 5.3 percent on Monday, following the announcement of the workforce reduction and the share repurchase plan. The stock now trades around €79, about four percent below its 50-day moving average. Analysts, however, remain broadly bullish: all 13 covering the stock rate it a buy, and Berenberg recently trimmed its price target from $155 to $140 while maintaining its recommendation, arguing the market is grossly undervaluing the company’s oncology pipeline. Wells Fargo has also set a $140 target.

A Balance Sheet Built for a Pivot

BioNTech enters this transformation phase with a fortress-like balance sheet. At the end of March, liquidity and securities stood at €16.8 billion. That cushion funds not only the $1 billion buyback — which runs through May 2027 and will primarily serve equity compensation obligations — but also a sprawling R&D engine that burned €557 million in the first quarter alone.

Should investors sell immediately? Or is it worth buying BioNTech?

The financial strain is evident in the first-quarter results. Revenue tumbled to €118.1 million from €182.8 million a year earlier, and the net loss ballooned to €531.9 million. The COVID-19 vaccine business has shrunk, forcing BioNTech to repurpose its infrastructure. The company now expects full-year 2026 revenue of between €2.0 billion and €2.3 billion, still heavily propped by seasonal vaccine sales.

Restructuring with a Scalpel

To stem the cash drain and redirect resources, BioNTech is closing or downsizing several sites. The affected locations include Idar-Oberstein, Marburg, and the former CureVac plant in Tübingen in Germany, as well as a facility in Singapore. The restructuring is targeted to deliver annual savings of roughly $585 million by 2029.

Nearly all of the freed-up capital will flow into clinical development. The oncology pipeline now features 15 ongoing or planned Phase 3 studies by year-end. Key to the narrative are two candidates. Pumitamig, a bispecific antibody, entered five new pivotal studies early this year, targeting triple-negative breast cancer and non-small-cell lung cancer, among others. Gotistobart, developed with OncoC4, has already yielded Phase 3 data from the PRESERVE-003 trial showing a more than 50 percent reduction in the risk of death in certain lung cancer patients, though those results still require confirmatory testing.

The Year-End Prize

Multiple clinical readouts are expected in the second half of 2026, with seven late-stage data packages from immunomodulator and antibody-drug conjugate programs. But the most critical date on the calendar remains the potential first regulatory approval for a proprietary cancer therapy. If BioNTech can deliver on that promise, the current share price — which reflects deep skepticism about the transition — could begin to reprice. Until then, the company is running a high-stakes strategy: spend heavily, shrink aggressively, and hope the science delivers before the cash pile begins to look less formidable.

Ad

BioNTech Stock: New Analysis - 12 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH | boerse | 69314418 |